Compare · CI vs PMD
CI vs PMD
Side-by-side comparison of The Cigna Group (CI) and Psychemedics Corporation (PMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CI and PMD operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $76.60B, about 1917.0x PMD ($40.0M).
- CI has hit the wire 8 times in the past 4 weeks while PMD has been quiet.
- CI has more recent analyst coverage (25 ratings vs 0 for PMD).
- Company
- The Cigna Group
- Psychemedics Corporation
- Price
- $289.60+1.16%
- $2.68-3.60%
- Market cap
- $76.60B
- $40.0M
- 1M return
- +3.64%
- -
- 1Y return
- -0.95%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 0
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Psychemedics Corporation
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, PCP, amphetamines, opiates, synthetic cannabinoids, and benzodiazepines. Its testing results provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data that can show a pattern of individual drug use over a longer period-of-time. The company provides its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was founded in 1986 and is headquartered in Acton, Massachusetts.
Latest CI
- Cigna Healthcare Expands AI-Enabled Personalized Support to Help More Customers Access Care Earlier and Improve Affordability
- The Cigna Group Declares Quarterly Dividend
- New insider Holgerson Bryan claimed ownership of 7,693 shares (SEC Form 3)
- New insider Kautzner Adam claimed ownership of 13,533 shares (SEC Form 3)
- New insider Sadler Jason D claimed ownership of 34,705 shares (SEC Form 3)
- New insider Sanford Paul A claimed ownership of 4,073 shares (SEC Form 3)
- New insider Perlberg Matthew claimed ownership of 9,345 shares (SEC Form 3)
- The Cigna Group's Second Quarter 2026 Earnings Release Details
- Evernorth Launches Pharmacy Forward: A Simpler, Faster Specialty Pharmacy Experience for Patients Managing Complex Conditions
- The Cigna Group Foundation Honors David M. Cordani's Leadership with New Grant to Strengthen Military Communities
Latest PMD
- Psychemedics Releases 2026 Education Insights Report
- Psychemedics Releases 2026 Workforce Insights Report
- Psychemedics Releases 2025 Workforce Insights Report
- Psychemedics Launches Groundbreaking Quartile Reporting for Enhanced Drug Testing Insights
- SEC Form 15-12G filed by Psychemedics Corporation
- Large owner Powell Anderson Capital Partners Llc bought $305,439 worth of shares (159,700 units at $1.91) (SEC Form 4)
- SEC Form 25 filed by Psychemedics Corporation
- Large owner Powell Anderson Capital Partners Llc bought $231,849 worth of shares (86,991 units at $2.67) (SEC Form 4)
- Amendment: SEC Form SC 13D/A filed by Psychemedics Corporation
- Director Kamin Peter sold $753,664 worth of shares (320,708 units at $2.35) (SEC Form 4)